Home › NCT06552052

A Retrospective and Prospective Natural History of Genetic Vasculopathies

Who can join

29 Days · All sexes

Inclusion Criteria:

* Confirmed ACTA2 pathogenic variant
* Available medical records since birth that permit documentation of disease characteristics and developmental milestone
* Have two parents and/or legal guardians who are English speaking and are able to read, understand, and sign the informed consent
* Able to tolerate travel to study site

Exclusion Criteria:

* Patient does not meet the inclusion criteria
* Patient is currently pregnant

About the study

This study will combine retrospective review of medical records from patients with ACTA2 and ongoing collection of clinical data using standardized instruments and intervals on an observational basis from patients with ACTA2.

Patients in cohorts 1-3 will be asked to attend clinic visits in person per the schedule of events. At minimum, the medical records of patients with ACTA2 will be reviewed to record data on aspects of the disease, including disease characteristics and developmental milestones. The study is planned to enroll a total of 100 patients: 7 in cohort 1, 7 in cohort 2, and the remaining in cohorts 3 and 4.

This study is planned to study patients for at least 3 years with the option to continue as long as possible for assessment of disease progression. During their continued study participation, as patients age, they may move into the next cohort. Beyond 3 years the duration of the study with be determined by availability of funding from sponsors.

Sponsor: Massachusetts General Hospital · Participants: 50 · Started: May 8, 2024

Contact the study team

• Anna V Lynch, BA · Phone: 617-949-6960

Official record on ClinicalTrials.gov — NCT06552052

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.